Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

5-Amino-1MQ: Dosage, Benefits, FDA Status & Clinics (2026)

What Is 5-Amino-1MQ? 5-Amino-1MQ targets one of the most overlooked enzymes in metabolic biology — nicotinamide N-methyltransferase, or NNMT — and blocks it. That single action has downstream effects on fat cell metabolism, NAD⁺ availability, and potentially o

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

What Is 5-Amino-1MQ?

5-Amino-1MQ targets one of the most overlooked enzymes in metabolic biology — nicotinamide N-methyltransferase, or NNMT — and blocks it. That single action has downstream effects on fat cell metabolism, NAD⁺ availability, and potentially on aging-related cellular decline. It's a small molecule, taken orally, and it's generated real interest in the longevity and metabolic research communities. The catch: every meaningful result so far has come from animal studies. No completed human clinical trials exist.

The compound's full name is 5-amino-1-methylquinolinium. It was developed specifically to probe what happens when you remove NNMT's brake on the NAD⁺ salvage pathway — and the preclinical data has been compelling enough that it's found its way into the gray-market research chemical space. Whether that translates to humans the way the mouse data suggests is still genuinely unknown.

If you're looking at this page because you're considering using it, or because a clinic has mentioned it, the most important thing to understand upfront is where the evidence actually stands: preclinical, not clinical. That doesn't mean it's without promise. It means the human chapter hasn't been written yet.

5-Amino-1MQ is a selective NNMT inhibitor — it blocks an enzyme that suppresses NAD⁺ production and promotes fat storage, particularly in adipose tissue.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Frequently Asked Questions About 5-Amino-1MQ

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.

Source: peptidemind.com ↗
Research context

Read sources and limitations before applying a claim.

Research review and sources

Reviewed by: PeptideUniv Updated: March 26, 2026 Human trial evidence exists, but the practical takeaways still depend on population, endpoint, and how long the compound has been studied. Key research takeaways surfaced on this page Research context available in the underlying profile. Primary references and supporting sources Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction — Recent 5A1MQ preclinical paper covering obesity, glucose, and liver outcomes. Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome — Review article that explains the rationale for targeting NNMT in metabolic research.

Source: peptideuniv.com ↗

Research Indications

Significantly increases cellular NAD+ levels by inhibiting NNMT enzyme, supporting cellular energy production and DNA repair mechanisms essential for healthy aging. Improves mitochondrial biogenesis and efficiency, enhancing cellular energy production and reducing oxidative stress markers associated with aging. Enhanced NAD+ availability supports sirtuins and other longevity pathways involved in DNA repair, cellular maintenance, and stress resistance. Improvement through enhanced mitochondrial efficiency. Enhancement via cellular energy optimization. Improved glucose/fat substrate switching. Supports increased basal metabolic rate. Improvements in fat burning capacity.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

5-Amino-1MQ Dosage Protocols

Standard Fat Loss Protocol 50 mg Once daily with food 8-12 weeks Accelerated Protocol 100 mg/day (50 mg twice daily) Twice daily with meals Metabolic Stack Protocol 50-100 mg/day oral Once or twice daily Standard Fat Loss Protocol: Start here to assess tolerance. Take with breakfast or lunch. Avoid taking late in the day on the off chance it affects sleep (rare but reported). Most users see gradual results starting around week 4. Accelerated Protocol: Split the dose between breakfast and lunch. This is the upper range commonly used. Do not exceed 100 mg/day without medical guidance. Better results when combined with regular exercise and a moderate caloric deficit. Metabolic Stack Protocol: When stacking with MOTS-c or a GLP-1 agonist, start at 50 mg/day and increase only if well tolerated. The combination targets multiple metabolic pathways simultaneously, so starting conservatively is wise. These are general guidelines for research purposes. Always consult a healthcare professional before use.

Source: peptidesexplorer.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →